Nanomedicine for the targeted treatment of venous thromboembolism - Vienna 2024

Pulmonary embolism: current management and future challenge

Chair(s): Casper Falster, Francis Couturaud

Session type: Oral presentation

Nanomedicine for the targeted treatment of venous thromboembolism

Remedios Otero Candelera

EVENTS HOME

Previous presentation

Next presentation

Session content

Nanomedicine for the targeted treatment of venous thromboembolism

Remedios Otero Candelera

Replay

Abstract

Slides

Catheter-directed therapies in patients with high-risk or intermediate-high-risk acute symptomatic pulmonary embolism with recent bleeding or high risk of bleeding. Analysis of implementing pulmonary embolism response team (PERT).

Sergio Lopez Ruz

Replay

Poster

Abstract

Slides

Effect of genetic variants on bleeding with rivaroxaban in pulmonary embolism patients: A multicenter prospective cohort study

Zhu Zhang

Replay

Abstract

Slides

Haemoptysis risk in lung cancer associated thrombosis (L-CAT) patients who initiated anticoagulant therapy.

Christophe Marie-sainte

Replay

Poster

Abstract

Slides

Effects of tinzaparin on the presence of residual thrombus in patients with cancer-associated thrombosis

Luis Jara-palomares

Replay

Poster

Abstract

Slides

Phase-Resolved Functional Lung (PREFUL)-MRI-derived parameters in evaluating chronic thromboembolic pulmonary disease: a prospective study

Linfeng Xi

Replay

Poster

Abstract

Slides

Use of inhaled nitric oxide in submassive intermediate-risk pulmonary embolism: a single-centre experience

Durre Shahwar

Replay

Abstract

Slides

Add-on GLP-1 agonists in the treatment of intermediate risk acute pulmonary embolism: a biomarker-driven proof-of-concept study

Chinthaka Samaranayake

Replay

Abstract

Slides

Genetic Insights through Chinese VTE Pedigree Interpretation Using the ACMG Method: Unraveling Potencial Genetic Risk Factors

Zhu Zhang

Replay

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}